Gastric cancer is one of the most prevalent malignancies in the world, but there is substantial variation in the incidence and mortality rate of the disease among different regions or countries.1 2 Chile is one of the countries with the highest reported frequencies.' 3 There is increasing evidence that cancers arise as the result of an accumulation of genetic alterations that interfere with normal control of cell growth and differentiation. Tumour suppressor genes are normal cellular genes, which when inactivated lead to a dysregulation of both the cell cycle and apoptosis. These disturbances may facilitate the development of neoplasia. 4 Cancer cells differ from normal cells in many important characteristics including loss of differentiation, increased invasiveness, and decreased drug sensitivity. There is evidence that conversion of normal epithelial cells to cancerous cells is a multistep process that requires the accumulation of multiple gene abnormalities affecting DNA repair genes, oncogenes, and tumour suppressor genes.56 Gastric cancer is no exception and it displays multiple gene alterations involving oncogenes, growth factor or cytokine genes, cell cycle regulatory genes, tumour suppressor genes, and cell adhesion molecule genes. These gene alterations may lead to genetic instability.7
The p53 tumour suppressor gene is located on the short arm of human chromosome 17 at position 17p 13.1. This gene is composed of 11 exons, the first of which is non-coding, and is localised 8-10 kb away from exons 2-11 89 The product of p53 gene is a 375 amino acid (with a molecular mass of -53 kDa) nuclear phosphoprotein, which was first identified as a cellular protein in 1979 because it formed a tight complex with the SV40 large T antigen.'0 The p53 protein was found in very low quantities in normal cells, but large quantities of p53 (5- tumours (13%) also showed focal weak nuclear 2/7 (29) staining (fig 3) . All cases that showed nuclear t0/39 (51) hsp72/73 expression were also p53 positive. .1/17 (65) Cytoplasmic hsp72/73 was also detected in 4/9 (44) non-neoplastic mucosa adjacent to the tu-7/20 (35) mours, mainly in intestinal metaplasia areas.
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Seven cases (15%) showed p53 and .8/41 (44) hsp72/73 coexpression with immunoreactivity 5/33 (45) for both proteins in the same neoplastic cell, 5/9 (56) 1/2 (50) 1/2 (50) 
